Seres Therapeutics, Inc. (MCRB): Price and Financial Metrics


Seres Therapeutics, Inc. (MCRB): $5.53

0.02 (+0.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MCRB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MCRB POWR Grades

  • Growth is the dimension where MCRB ranks best; there it ranks ahead of 46.61% of US stocks.
  • The strongest trend for MCRB is in Value, which has been heading down over the past 177 days.
  • MCRB ranks lowest in Momentum; there it ranks in the 5th percentile.

MCRB Stock Summary

  • With a price/sales ratio of 51.33, SERES THERAPEUTICS INC has a higher such ratio than 96.24% of stocks in our set.
  • Over the past twelve months, MCRB has reported earnings growth of 633%, putting it ahead of 97.27% of US stocks in our set.
  • Revenue growth over the past 12 months for SERES THERAPEUTICS INC comes in at -91.39%, a number that bests just 1.25% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SERES THERAPEUTICS INC are ADAP, CRIS, TGTX, RXRX, and CRBU.
  • Visit MCRB's SEC page to see the company's official filings. To visit the company's web site, go to www.serestherapeutics.com.

MCRB Valuation Summary

  • In comparison to the median Healthcare stock, MCRB's price/earnings ratio is 112.33% lower, now standing at -2.8.
  • Over the past 92 months, MCRB's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MCRB.

Stock Date P/S P/B P/E EV/EBIT
MCRB 2023-01-20 48.5 9.6 -2.8 -2.3
MCRB 2023-01-19 47.6 9.4 -2.8 -2.2
MCRB 2023-01-18 49.0 9.7 -2.8 -2.3
MCRB 2023-01-17 49.9 9.9 -2.9 -2.3
MCRB 2023-01-13 51.1 10.1 -3.0 -2.4
MCRB 2023-01-12 51.3 10.2 -3.0 -2.4

MCRB Growth Metrics

    The 2 year revenue growth rate now stands at 297.77%.
  • Its 3 year net cashflow from operations growth rate is now at 55.81%.
  • Its year over year cash and equivalents growth rate is now at 142.38%.
Over the past 33 months, MCRB's revenue has gone down $21,131,000.

The table below shows MCRB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13.374 -227.787 -231.362
2022-06-30 136.655 -40.463 -103.142
2022-03-31 140.702 -30.261 -86.737
2021-12-31 144.927 6.688 -65.578
2021-09-30 155.27 40.624 -33.829
2021-06-30 29.962 -112.984 -132.327

MCRB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MCRB has a Quality Grade of C, ranking ahead of 46.12% of graded US stocks.
  • MCRB's asset turnover comes in at 0.094 -- ranking 268th of 680 Pharmaceutical Products stocks.
  • ABEO, VXRT, and ARWR are the stocks whose asset turnover ratios are most correlated with MCRB.

The table below shows MCRB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.094 1 -0.662
2021-03-31 0.111 1 -0.642
2020-12-31 0.146 1 -0.751
2020-09-30 0.133 1 -1.134
2020-06-30 0.247 1 -1.379
2020-03-31 0.276 1 -1.299

MCRB Price Target

For more insight on analysts targets of MCRB, see our MCRB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.57 Average Broker Recommendation 1.5 (Moderate Buy)

MCRB Stock Price Chart Interactive Chart >

Price chart for MCRB

MCRB Price/Volume Stats

Current price $5.53 52-week high $9.49
Prev. close $5.51 52-week low $2.50
Day low $5.45 Volume 909,100
Day high $5.64 Avg. volume 637,589
50-day MA $5.94 Dividend yield N/A
200-day MA $5.32 Market Cap 688.99M

Seres Therapeutics, Inc. (MCRB) Company Bio


Seres Therapeutics is a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company was founded in 2010 and is based in Cambridge, Massachusetts.


MCRB Latest News Stream


Event/Time News Detail
Loading, please wait...

MCRB Latest Social Stream


Loading social stream, please wait...

View Full MCRB Social Stream

Latest MCRB News From Around the Web

Below are the latest news stories about SERES THERAPEUTICS INC that investors may wish to consider to help them evaluate MCRB as an investment opportunity.

Seres Therapeutics Inc. (MCRB) can excel with these strategies

In Thursday’s session, Seres Therapeutics Inc. (NASDAQ:MCRB) marked $5.11 per share, down from $5.26 in the previous session. While Seres Therapeutics Inc. has underperformed by -2.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCRB fell by -30.76%, with highs and lows ranging from $9.49 to […]

US Post News | January 20, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., January 13, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees, consisting of stock options to purchase an aggregate of 9,000 shares of common stock and restricted stock units ("RSUs"), coverin

Yahoo | January 13, 2023

Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress

CAMBRIDGE, Mass., January 05, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors. Dr. Fraser will begin serving on Seres’ Board, effective immediately.

Yahoo | January 5, 2023

Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST. An audio webcast of the presentation will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and wil

Business Wire | January 4, 2023

Seres Therapeutics (MCRB) Investor Presentation - Slideshow (NASDAQ:MCRB)

The following slide deck was published by Seres Therapeutics, Inc.

Seeking Alpha | December 9, 2022

Read More 'MCRB' Stories Here

MCRB Price Returns

1-mo 7.59%
3-mo -31.47%
6-mo 34.55%
1-year -25.57%
3-year 71.74%
5-year -49.82%
YTD -1.25%
2022 -32.77%
2021 -66.00%
2020 610.14%
2019 -23.67%
2018 -55.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6395 seconds.